Antifungals-Systemic

Systemic antifungals comprise a diverse therapeutic group of medications administered orally or parenterally to treat internal, invasive, or severe fungal infections throughout the body Clinically, systemic antifungals are essential for treating life-threatening invasive candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses, as well as managing recalcitrant mucocutaneous infections and providing targeted prophylaxis in immunocompromised patient populations

Spanning multiple chemical classes—including triazoles, echinocandins, polyenes, and allylamines—these agents exert fungicidal or fungistatic activity by disrupting vital fungal cell structures, primarily by inhibiting ergosterol biosynthesis, binding directly to membrane ergosterol, or blocking fungal cell wall synthesis

Spanning multiple chemical classes—including triazoles, echinocandins, polyenes, and allylamines—these agents exert fungicidal or fungistatic activity by disrupting vital fungal cell structures, primarily by inhibiting ergosterol biosynthesis, binding directly to membrane ergosterol, or blocking fungal cell wall synthesis

Spanning multiple chemical classes—including triazoles, echinocandins, polyenes, and allylamines—these agents exert fungicidal or fungistatic activity by disrupting vital fungal cell structures, primarily by inhibiting ergosterol biosynthesis, binding directly to membrane ergosterol, or blocking fungal cell wall synthesis

Clinically, systemic antifungals are essential for treating life-threatening invasive candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses, as well as managing recalcitrant mucocutaneous infections and providing targeted prophylaxis in immunocompromised patient populations

Clinically, systemic antifungals are essential for treating life-threatening invasive candidiasis, invasive aspergillosis, cryptococcal meningitis, and endemic mycoses, as well as managing recalcitrant mucocutaneous infections and providing targeted prophylaxis in immunocompromised patient populations